Related Experiment Video
Updated: Jun 17, 2026
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
[Anticancer effects of a novel indolinone compound in nasopharyngeal carcinoma cells]
Ming-qun Wang1, Yi-nan Liu, Xiang Zhao
1Department of Cell Biology, Peking University School of Basic Medical Sciences, Beijing 100191, China.
Objective:
To develop novel targeted anticancer medicines for effective treatment of nasopharyngeal carcinoma (NPC), a prevalent malignant disease in southern China and southeast Asia.
Methods:
CNE cells were treated with a novel indolinone IF239 synthesized by our research group. Cell viability was determined by the acid phosphatase assay (APA). Morphologic changes and adhesion status of CNE cells treated with IF239 were observed under a light microscope. Flow cytometry was used to analyze the cell cycle phases . Key regulating molecules in the cell cycle progression were detected by Western blotting.
Results:
IF239 had potent cytotoxic effect on CNE cells. The possible antitumor mechanisms of IF239 involved inhibition of cell adhesion and cell cycle arrest in the G2/M phase. Moreover, G2/M arrest caused by IF239 was related to up-regulation of both cyclin B1 and the phosphorylation level of CDK1.
Conclusion:
IF239 has high anticancer activity over CNE cells, and has unique anticancer mechanisms, suggesting that IF239 has promising application potentials.
Insights
A novel indolinone, IF239, shows potent anticancer activity against nasopharyngeal carcinoma (NPC) cells by inhibiting cell adhesion and causing cell cycle arrest. This suggests IF239 has promising therapeutic potential for NPC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia.
- Development of novel targeted anticancer agents is crucial for effective NPC treatment.
Purpose of the Study:
- To develop and evaluate a novel indolinone derivative, IF239, as a potential targeted anticancer medicine for NPC.
- To investigate the anticancer mechanisms of IF239 in NPC cells.
Main Methods:
- CNE cells were treated with synthesized indolinone IF239.
- Cell viability was assessed using the acid phosphatase assay (APA).
- Cell morphology, adhesion, cell cycle progression (flow cytometry), and key regulatory molecules (Western blotting) were analyzed.
Main Results:
- IF239 demonstrated significant cytotoxic effects on CNE cells.
- Antitumor mechanisms included inhibition of cell adhesion and G2/M phase cell cycle arrest.
- G2/M arrest was associated with increased cyclin B1 and phosphorylated CDK1 levels.
Conclusions:
- IF239 exhibits potent anticancer activity against NPC cells.
- Unique mechanisms involving cell adhesion inhibition and cell cycle arrest highlight IF239's therapeutic potential.
- IF239 represents a promising candidate for further development as an NPC therapeutic agent.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...